Advertisement

Topics

Themis Company Profile

08:41 EST 16th December 2018 | BioPortfolio

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.


News Articles [14 Associated News Articles listed on BioPortfolio]

Themis Bioscience Announces Exclusive Licensing Agreement with Max-Planck-Innovation to Develop ...

-- Themis to expand measles vector immunomodulation portfolio into oncology indications-- Read more...

Themis gets oncology-related IP from Max Planck

Max Planck Innovation GMBH licensed Themis Bioscience GMBH exclusive worldwide rights to develop, manufacture, and commercialize cancer therapies based on an oncolytic measles virus platform.

EMA grants PRIME designation to Themis' chikungunya vaccine candidate

Themis announced today that the European Medicines Agency has granted PRIority MEdicines designation to its most advanced program in development, a vaccine to prevent chikungunya fever.

Max Planck Partners with Themis Bioscience to Develop Oncolytic Virotherapies

Themis Bioscience said it will expand its measles vector immunomodulation portfolio into immuno-oncology through an exclusive global license agreement with the technology transfer agency of the Max Pl...

CHIKUNGUNYA VACCINE DEVELOPMENT TOWARDS PHASE III TRIALS BOOSTED BY INNOVATE UK

Vienna, 5th September 2017 – The further development of a promising Chikungunya vaccine candidate by Themis Bioscience is now supported with 3 Mio. GBP by the United Kingdom’s innovation agenc...

Themis, Max-Planck-Innovation sign license agreement to develop and commercialize oncolytic virotherapies

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwid...

Themis postpones IPO

Themis launches terms of IPO

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Themis-associated phosphatase activity controls signaling in T cell development.

Thymocyte-expressed molecule involved in selection (Themis) has been shown to be important for T cell selection by setting the threshold for positive versus negative selection. Themis interacts with t...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI

To date there is very little PD and pharmacokinetic (PK) data on the ticagrelor 60 mg bid dosing regimen. In particular, there is no prospective PK/PD study on this dosing regimen in patie...

Companies [2 Associated Companies listed on BioPortfolio]

Themis

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

Themis Bioscience

Themis is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating...

More Information about "Themis" on BioPortfolio

We have published hundreds of Themis news stories on BioPortfolio along with dozens of Themis Clinical Trials and PubMed Articles about Themis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Themis Companies in our database. You can also find out about relevant Themis Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...


Corporate Database Quicklinks



Searches Linking to this Company Record